首页> 外文期刊>Pakistan journal of medical sciences. >A study of Galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm
【24h】

A study of Galactin-3 on fine needle aspiration as a diagnostic marker differentiating benign from malignant thyroid neoplasm

机译:Galectin-3在细针穿刺上作为鉴别良恶性甲状腺肿瘤的诊断指标的研究

获取原文
       

摘要

Background & Objective: Thyroid nodules are very common in our setup and their diagnosis on fine needle aspiration is not easy and is a taxing affair. It is a challenge to differentiate between follicular adenoma and follicular carcinoma without histology. Our objective was to investigate the role of Galectin-3 in fine needle aspirates of thyroid nodules as a prospective diagnostic marker and consequently its ability to differentiate benign from malignant neoplasms.Methods: The research was conducted at the department of Pathology, King Edward Medical University, in association with other teaching institutions of Lahore from June 2012 to July 2014. Sixty cases of solitary thyroid nodules were included in the study. Haematoxylin and eosin staining of the fixed smears and Galectin-3 immunohistochemical staining of the sections prepared from the cell block was performed.Results: There were 60 patients in our study with a mean age of 33.35 years. The Bethesda system for reporting thyroid cytopathology was used to classify the smears and only categories IV, V and VI were included. On histological examination of the resected nodules there were 38.3% (23/60) cases of follicular adenoma, 46.6% (28/60) were of papillary carcinoma and follicular carcinoma made up to 15% (9/60) of all cases. Galectin-3 was negative in 100% (23/23) cases of follicular adenomas. Out of 37 malignant cases 65% lesions showed positivity, while 35% showed negativity for this immunomarker. Considering the malignant lesions, 75% cases of papillary carcinomas showed a positive reaction while only 33% of follicular carcinomas were positive for the immunomarker. This showed that the positive expression was more common in papillary as compared to follicular carcinomas.Conclusion: Galectin-3immunomarker is considerably expressed in malignant tumors, but it is not expressed in benign follicular lesions.
机译:背景与目的:甲状腺结节在我们的装置中很常见,对细针穿刺的诊断并不容易,而且很麻烦。在没有组织学的情况下区分滤泡性腺瘤和滤泡性癌是一个挑战。我们的目的是研究Galectin-3在甲状腺结节细针穿刺中作为前瞻性诊断标志物的作用,并因此探讨其区分良性和恶性肿瘤的能力。方法:这项研究是在爱德华国王医科大学病理学系进行的于2012年6月至2014年7月与拉合尔的其他教学机构合作。该研究包括60例甲状腺孤立结节。进行了苏木精和伊红的固定涂片染色以及从细胞块制备的切片的Galectin-3免疫组化染色。结果:本研究有60例患者,平均年龄为33.35岁。使用用于报告甲状腺细胞病理学的Bethesda系统对涂片进行分类,仅包括IV,V和VI类。对切​​除的结节进行组织学检查时,有38.3%(23/60)的滤泡状腺瘤病例,有46.6%(28/60)的是乳头状癌,滤泡癌占所有病例的15%(9/60)。 Galectin-3在100%(23/23)滤泡性腺瘤病例中呈阴性。在37例恶性肿瘤中,有65%的病变显示阳性,而35%的病变对该免疫标记阴性。考虑到恶性病变,75%的乳头状癌病例显示阳性反应,而只有33%的滤泡癌的免疫标记阳性。这表明与滤泡状癌相比,在乳头状癌中阳性表达更为普遍。结论:Galectin-3免疫标记物在恶性肿瘤中大量表达,但在良性滤泡性病变中不表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号